January 18, 2012

Provectus Receives Guidance From FDA On Pathway to Approval for Phase 3 Trial of PV-10 For Metastatic Melanoma

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com) has received guidance from the U.S. Food and Drug Administration ("FDA") to submit its Phase 3 protocol for review, either via standard review or a request for Special Protocol Assessment ("SPA"). This guidance was in response to Provectus's request of a final end-of-Phase 2 meeting to achieve consensus on design of a planned pivotal Phase 3 randomized controlled trial ("RCT") of PV-10 for metastatic melanoma.

January 17, 2012

PV-10 Mechanism of Action Data to Be Presented at the Society of Surgical Oncology Annual Meeting March 21-24, 2012 in Orlando, Florida

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com) announces that nonclinical data on the immunologic mechanism of action of PV-10 will be presented at the Society of Surgical Oncology Annual Meeting, March 21-24, 2012, at the Orlando World Center Marriott in Orlando, Florida.

January 17, 2012

Provectus Pharmaceuticals Will Present at the Noble Financial Capital Markets' Eighth Annual Equity Conference on January 18, 2012

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com) announced today that Craig Dees, Ph.D., CEO, will present at BOCEMb: Noble Financial Capital Markets' Eighth Annual Equity Conference on January 18, 2012 at 1:00 PM EST.

December 20, 2011

Provectus Pharmaceuticals, Inc. and Its Subsidiaries Complete Unregistered Offering of Units to Facilitate Spin-off of Pure-ific Corporation

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com) announced today that it and its five wholly owned subsidiaries, Pure-ific Corporation, Provectus Biotech, Inc., Provectus Devicetech, Inc., Provectus Imaging, Inc., and Xantech Pharmaceuticals, Inc. (the "Subsidiaries"), have completed an unregistered offering of Units pursuant to the exemption from registration requirements under Rule 506 of Regulation D and Section 4(2) of the Securities Act of 1933.

November 29, 2011

Provectus Reports on Third End-of-Phase 2 Meeting with U.S. FDA to Define Pathway to Approval of PV-10 for Metastatic Melanoma

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com) has held its third end-of-Phase 2 meeting with the U.S. Food and Drug Administration ("FDA"). The meeting, held October 18, 2011, addressed several topics central to definition of the applicable patient population and primary endpoint for the Company's planned pivotal Phase 3 randomized controlled trial ("RCT") of PV-10 for metastatic melanoma.

November 14, 2011

Data on Provectus's PV-10 For Metastatic Melanoma Presented at the 2011 International Melanoma Congress

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com) announced that data and study design features on PV-10 for metastatic melanoma were presented at the 2011 International Melanoma Congress on November 12, 2011, during the 5th Meeting of Interdisciplinary Melanoma/Skin Cancer Centres meeting, in Tampa, Florida.